SEAGULL HEALTH
Your health,We care!
Olverembatinib Tablets can potently inhibit the T315I resistant mutation, with convenient administration and a controllable safety profile.
AuthenticGuaranteeFast DeliveryPrivacy Olverembatinib Tablets is a domestically innovative Class 1 drug independently developed in China, belonging to the third-generation BCR-ABL tyrosine kinase inhibitors.
In clinical practice, it is administered orally at a dose of 40 mg every other day with a controllable safety profile, bringing new hope for survival to patients with drug-resistant hematological malignancies.
Olverembatinib Tablets are indicated for the treatment of adult patients in the chronic phase of chronic myeloid leukemia (CML) who are resistant and/or intolerant to first-generation and second-generation tyrosine kinase inhibitors (TKIs).
Olverembatinib Tablets are indicated for adult patients in the chronic or accelerated phase of chronic myeloid leukemia (CML) who are resistant to any tyrosine kinase inhibitor and diagnosed with T315I mutation by a fully validated detection method. This indication is granted conditional approval based on the response rates from a single-arm clinical trial (major cytogenetic response rate for the chronic phase, complete hematologic response rate for the accelerated phase).
The recommended dose is 40 mg, administered once every two days (every other day), taken orally with meals, and continued until disease progression or unacceptable toxicity in patients. The dose may be taken at any time of the day, but it is advisable to take it at approximately the same fixed time each day.
If a dose of Olverembatinib Tablets is missed, the missed dose should be taken within 4 hours. If more than 4 hours have elapsed, the missed dose should not be taken. In case of vomiting after administration, no additional dose should be taken. The tablets must be swallowed whole and must not be crushed or split. For chronic-phase patients who do not achieve complete hematologic response within 3 months, or accelerated-phase patients who show no hematologic response within 6 months, the treating physician shall decide whether to continue the administration of Olverembatinib Tablets.
During the administration of Olverembatinib Tablets, patients are advised to avoid direct exposure to sunlight as much as possible or take appropriate sun protection measures.
Caution should be exercised when administering Olverembatinib Tablets to patients who may be exposed to prolonged and intensive direct sunlight due to occupational reasons, or patients with inherent photosensitivity.
Olverembatinib Tablets are contraindicated in patients with hypersensitivity to the active ingredient or any excipients of the product.
Common adverse reactions (incidence ≥10%) during treatment include thrombocytopenia, leukopenia, anemia, elevated liver enzymes, increased blood bilirubin, skin hyperpigmentation, hypertriglyceridemia, proteinuria, neutropenia, etc.
All grade 3 or higher adverse reactions with an incidence of ≥10% occur in the hematologic system, including thrombocytopenia, leukopenia/neutropenia, and anemia.
For more detailed drug information, please consult the official package leaflet.
Olverembatinib is a targeted therapy drug indi···...【详情】
Olverembatinib is a targeted therapy agent pri···...【详情】
The daily dosage of olverembatinib must be str···...【详情】
Olverembatinib is a targeted therapy for speci···...【详情】
Olverembatinib is a targeted therapy indicated···...【详情】
If any issues arise, please contact us immediately.
Email:haiousales@gmail.com
Olverembatinib is a third-generation BCR-ABL tyrosine kinase inhibitor (TKI). It is primarily indicated for the treatment of specific types of leukemia, particularly in patients with chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant to conventional TKI therapies or harbor the T315I gene mutation.
Yes, Olverembatinib is a targeted therapy drug classified as a tyrosine kinase inhibitor. It exerts specific action on designated molecular targets (e.g., BCR-ABL fusion protein) to inhibit cancer cell proliferation.
Yes, home delivery is available! You are required to provide a valid prescription. Based on our compliant qualifications, we will arrange delivery through designated logistics providers, strictly adhering to pharmaceutical transportation standards to ensure the safe arrival of the medication.
Copyright 2024 @ haiouhealth.com All right reserved SEAGULL HEALTH
